Alnylam Grants Calando a License to Develop and Commercialize an RNAi Therapeutic Product
Target-Specific License for RNAi Intellectual Property Granted under Alnylam's InterfeRx(TM) Program
Advertisement
Alnylam Pharmaceuticals, Inc. has granted Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research Corporation, an InterfeRx(TM) license to discover, develop, and commercialize an RNAi therapeutic utilizing a synthetic siRNA, together exclusively with Calando's proprietary delivery technology, that is directed towards a cancer target. As part of the agreement, Calando also has an option to acquire an InterfeRx license for a second target gene. Detailed financial terms were not disclosed, but include upfront, annual, and milestone payments, and royalties on sales of any products covered by the licensing agreement.